What does this research mean for the field?

Baricitinib demonstrates sustained real-world effectiveness and retention over 24 months in patients with rheumatoid arthritis, including difficult-to-treat cases, with early improvements in pain and fatigue predicting long-term clinical remission. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the real-world effectiveness, patient-reported outcomes, and 24-month retention of baricitinib in Japanese patients with rheumatoid arthritis, including difficult-to-treat populations.

August 30, 2026Modern Rheumatology

Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan

View Full Paper

Ask AI

Bookmark

Authors

KIKei IkedaDokkyo Medical University TKTaisuke KojimaEli Lilly (Japan)NTNaoto TsujimotoEli Lilly (Japan)

Discussion

Member takes

Implication

Observational study demonstrates sustained effectiveness and retention of baricitinib in rheumatoid arthritis, indicating its clinical utility even in difficult-to-treat disease.

Key Points

To evaluate the real-world effectiveness, patient-reported outcomes, and 24-month retention of baricitinib in Japanese patients with rheumatoid arthritis, including difficult-to-treat populations.
A 24-month observational study enrolled patients initiating baricitinib in Japan, stratified by baseline Clinical Disease Activity Index (CDAI) scores and prior biologic or targeted synthetic DMARD use.
Outcomes included time-to-discontinuation, CDAI remission or low disease activity, and changes in patient-reported outcomes, analyzed using multivariable-adjusted logistic regression.
Treatment retention at 24 months reached 58.2% across overall patients (N=353) and 42.0% in patients with difficult-to-treat disease (N=88), with primary non-response driving 11.0% of discontinuations.
CDAI remission was achieved by 36.4% of overall patients and 22.9% of difficult-to-treat patients at 24 months.
Mean improvements in patient-reported outcomes included changes in disease activity (-21.7 mm), disability index (-0.360), and pain (-24.9 mm), while 55.9% of retained baseline steroid users successfully discontinued glucocorticoids.

Cite This Study

Ikeda et al. (2026) studied this question.

synapsesocial.com/papers/6a941ce46c1a8fb52e79e784 https://doi.org/10.1093/mr/roag074

View Full Paper

Ask AI

Bookmark

Implication

Observational study demonstrates sustained effectiveness and retention of baricitinib in rheumatoid arthritis, indicating its clinical utility even in difficult-to-treat disease.

Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-World Outcomes of Baricitinib in Patients with Rheumatoid Arthritis: A Two-Year Observational Study of Overall and Difficult-to-Treat Patients in Japan

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider